Interestingly, this also suggests a link to recent studies on genomic tumor evolution, reporting on an increase in activating PIK3CA mutation among cell free tumor DNA of breast cancer patients, following paclitaxel treatment [53]. This evidence concerns the gene PIK3CA and breast carcinoma.